Methylprednisolone can help with COVID-19, but only in specific circumstances. It is recommended for hospitalized patients who need supplemental oxygen or are critically ill, where corticosteroids as a class have shown a clear mortality benefit. For mild cases or people recovering at home, guidelines recommend against using it because it may actually cause harm.
When Methylprednisolone Helps
Severe COVID-19 triggers an overblown immune response sometimes called a cytokine storm. Immune cells rapidly multiply and release massive amounts of inflammatory signals, which damage the lining of the lungs’ tiny air sacs and blood vessels. This causes fluid to leak into the lungs, making it progressively harder to get oxygen into the bloodstream. In the worst cases, this leads to acute respiratory distress syndrome (ARDS), the leading cause of death in COVID-19 patients.
Methylprednisolone is a potent anti-inflammatory steroid that dials down this runaway immune response. After treatment, key markers of inflammation in the blood drop significantly. That reduction in inflammation can lead to faster improvement in lung damage, easier breathing, and a lower chance of needing intensive care or a ventilator. One early analysis identified methylprednisolone as the most effective agent at targeting the specific inflammatory pathways responsible for COVID-related ARDS.
What the Guidelines Actually Recommend
Dexamethasone, not methylprednisolone, is the preferred corticosteroid for COVID-19. The landmark RECOVERY trial showed that dexamethasone reduced 28-day mortality by about 17% in hospitalized patients who needed supplemental oxygen. That trial established dexamethasone 6 mg daily for up to 10 days as the standard protocol, and most guidelines worldwide are built around that evidence.
Methylprednisolone is considered a reasonable alternative when dexamethasone is unavailable. The Infectious Diseases Society of America (IDSA) lists it as a pharmacologic substitute at an equivalent daily dose of 32 mg, which matches the anti-inflammatory potency of 6 mg of dexamethasone. Some clinical trials have tested higher doses, ranging from 60 mg daily up to 250 mg daily for short pulse courses, but there is less standardized evidence behind those regimens compared to dexamethasone.
The recommendations break down by how sick you are:
- Critically ill (on a ventilator): Corticosteroids are strongly recommended. Dexamethasone is preferred, but methylprednisolone at equivalent doses is an accepted alternative.
- Severe illness (oxygen levels at or below 94%): Corticosteroids are recommended. Again, dexamethasone is the first choice with methylprednisolone as a substitute.
- Mild to moderate illness (oxygen levels above 94%, no supplemental oxygen needed): Guidelines recommend against using any corticosteroid, including methylprednisolone.
Why It Can Be Harmful in Mild Cases
In the early days of a COVID-19 infection, your immune system is doing important work fighting the virus. Suppressing that response with a steroid before the disease becomes severe may actually give the virus more room to replicate and cause damage. The World Health Organization issued a conditional recommendation against corticosteroids in non-severe COVID-19, noting that low-certainty evidence suggested they could increase 28-day mortality in patients who weren’t seriously ill.
Beyond the timing problem, corticosteroids carry real side effects. Blood sugar spikes are common, especially in people with diabetes. Other risks include gastrointestinal bleeding, muscle weakness, sodium imbalances, neuropsychiatric effects like mood changes or insomnia, and secondary infections from a weakened immune system. Fungal infections became a well-documented concern during the pandemic among COVID-19 patients receiving steroids, particularly in certain regions. These risks are worth accepting when someone is fighting for their life on supplemental oxygen. They are not worth accepting for a mild infection that would resolve on its own.
How It Compares to Dexamethasone
Both drugs belong to the same class of corticosteroids and work through similar anti-inflammatory mechanisms. The main reason dexamethasone is preferred is simply that it has the most robust clinical trial data behind it. Methylprednisolone has some potential pharmacological advantages: it penetrates lung tissue well and has a shorter duration of action, which gives clinicians more flexibility in adjusting doses. Several randomized trials have compared the two head-to-head using various methylprednisolone doses, but the results haven’t been strong or consistent enough to displace dexamethasone as the default choice.
One practical difference is that methylprednisolone did not appear to significantly affect the duration of viral shedding, based on a WHO analysis. This was a concern early in the pandemic, since prolonging the period someone is contagious would create problems for infection control.
The Bottom Line on Timing and Eligibility
The oxygen level threshold is the key deciding factor. If your blood oxygen saturation is 94% or below on room air, or you already need supplemental oxygen, corticosteroids including methylprednisolone become part of the treatment picture. If your oxygen levels are fine and you’re managing symptoms at home, steroids are not indicated and could do more harm than good.
This holds true regardless of which SARS-CoV-2 variant is circulating. The 2025 WHO living guideline continues to support corticosteroid use in severe and critical COVID-19, and the underlying logic hasn’t changed: the drug targets the dangerous inflammatory phase of the disease, not the virus itself. Taking it too early, before that inflammatory phase kicks in, removes the benefit and leaves only the side effects.